MedPath

Clinical Trial of Shoolharan Yoga in Abdominal Pain

Not yet recruiting
Conditions
Other specified diseases of the digestive system,
Registration Number
CTRI/2019/09/021169
Lead Sponsor
Ashish Kumar Tripathi
Brief Summary

**PLAN OF STUDY**

1. **Selection of patients**: total 30 patients of abdominal pain will be selected from OPD/ IPD of Rishikul Campus, Haridwar. The study will be conducted on patients randomly divided into three groups that mean 10 patients in each group. Selection of patient will be done on detailed clinical history, physical examination & other required investigations irrespective of their gender, caste & greed.

2. **Selection of drug:**   sample 1 (*Shoolharan* *Yoga*), Sample-2 (*Shoolharan* *Yoga* with *bhavana* of *Shoolprashaman Mahakashaya*) will be used in group-1 & group-2 respectively and Mefanamic acid will be used as standard drug in group-3.

3**.  Dose of Drug**: 500 mg (for sample-1 & sample-2 each)

4. **Duration of study**: 60 days

5. **Types of study:** Single blind.

6**. Assessment & follow-up**: it will be done on same day after 30 min, 1 hour, 2 hour & 3 hours of drug intake & follow up will be done if required.

7. **Inclusion criteria**:

a). age group between 20-60 years.

b) Chronicity not more than 10 days.

c). Abdominal pain (Colicky type)

8.**Exclusion criteria**:

a). Age less than 20 & more than 60 years.

b). Traumatic condition

c). Cases which require urgent surgery

 **9. Criteria of withdrawal:**

a) Personal matters

b) Intercurrent illness

c) Aggregations of complaints

d) Any other difficulties

           10. **Criteria of assessment (Scoring criteria):**

Scoring will be done on the basis of severity of pain-

| | |

| --- | --- |

|**Severity of Pain**

**Score**

|No Pain

0

|Mild

1

|Moderate

2

|Severe

3

  Efficacy will be scored on the basis of time duration in reduction of severity of pain-

| | |

| --- | --- |

|**Time Duration**

**Score**

|Less than 1 hour

4

|1-3 hours

3

|3-5 hours

2

|5-7 hours

1

|No reduction in severity

0

 Frequency of the abdominal pain will be scored-

| | |

| --- | --- |

|**Repetition of Pain Episodes**

**Score**

|No Further Episode

0

|1-2 times/day

1

|3-4 times/day

2

|5-6 times/day

3

|More than 6 times/day

4

 11. **Observations**: Change in severity of associated symptoms will be observed along with abdominal pain.

**12. Investigation:** If necessary, to exclude surgical & gynaecological cases.

12. **Conclusion**: It will be done on basis of observation which is done on subjective parameters. The result will be analyzed statistically& discussed.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Chronicity not more than 10 days Abdominal pain (Colicky type).

Exclusion Criteria
  • Age less than 20 & more than 60 years.
  • Traumatic condition .
  • Cases which require urgent surgery.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Scoring will be done on the basis of severity of pain-Same day after 30 minutes, 1hour, 2hour & 3 hour of drug intake
No Pain0Same day after 30 minutes, 1hour, 2hour & 3 hour of drug intake
Mild Pain 1Same day after 30 minutes, 1hour, 2hour & 3 hour of drug intake
Moderate Pain 2Same day after 30 minutes, 1hour, 2hour & 3 hour of drug intake
Severe Pain 3Same day after 30 minutes, 1hour, 2hour & 3 hour of drug intake
Secondary Outcome Measures
NameTimeMethod
Frequency of the abdominal pain will be scored-Repetition of Pain EpisodesScore

Trial Locations

Locations (1)

Rishikul Govt. Ayurvedic College OPD of Kaychikitsa/Shalyatantra/ Strirog/ Prasutitantra/Rasashastra

🇮🇳

Hardwar, UTTARANCHAL, India

Rishikul Govt. Ayurvedic College OPD of Kaychikitsa/Shalyatantra/ Strirog/ Prasutitantra/Rasashastra
🇮🇳Hardwar, UTTARANCHAL, India
Ashish Kumar Tripathi
Principal investigator
08840148496
newcharak@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.